Relief Therapeutics to receive European patent covering RLF-TD011 for epidermolysis bullosa wound treatment: Geneva Tuesday, October 22, 2024, 13:00 Hrs [IST] Relief Therapeutics ...
GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ...
Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...
The study was designed to evaluate the effects of RLF-TD011 on microbiome diversity in wounds of patients with dystrophic and junctional EB. Microbiome analysis showed a statistically significant ...
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa ...
The study was designed to evaluate the effects of RLF-TD011 on microbiome diversity in wounds of patients with dystrophic and junctional EB. Microbiome analysis showed a statistically significant ...
GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback